Dipartimento di Medicina Interna e Specialistica DIMIS, Universitá di Palermo, Via del Vespro 141, Palermo, Italy.
Expert Opin Pharmacother. 2011 Mar;12(4):647-55. doi: 10.1517/14656566.2011.557359. Epub 2011 Feb 2.
Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia.
The effects of cilostazol on plasma lipids, lipoproteins, apolipoproteins and postprandial lipemia are reviewed. A literature search (using Medline and Scopus) was performed up to 24 October 2010. The authors also manually reviewed the references of selected articles for any pertinent material.
Cilostazol is able to significantly lower plasma triglyceride levels, with a concomitant increase in high-density lipoprotein (HDL) cholesterol concentrations. Additional effects on pro-atherogenic lipoproteins and apolipoproteins include those on remnant-like particles, HDL subclasses, apolipoprotein B and postprandial lipemia. Cilostazol can improve the pro-atherogenic lipid profile in patients with peripheral arterial disease or type 2 diabetes. Further studies are needed to establish whether cilostazol treatment exerts clinically relevant effects on atherogenic dyslipidemia in high-risk patients.
西洛他唑是一种可逆的、选择性磷酸二酯酶 3A（PDE3A）抑制剂，能够显著改善间歇性跛行患者的步行距离。然而，除了抗血小板和血管舒张作用外，西洛他唑似乎对动脉粥样硬化性血脂异常有显著影响。
本文综述了西洛他唑对血浆脂质、脂蛋白、载脂蛋白和餐后脂血症的影响。检索了截至 2010 年 10 月 24 日的 Medline 和 Scopus 数据库。作者还手动查阅了选定文章的参考文献，以获取任何相关材料。
西洛他唑能显著降低血浆甘油三酯水平，同时增加高密度脂蛋白（HDL）胆固醇浓度。对致动脉粥样硬化脂蛋白和载脂蛋白的其他影响包括残粒样颗粒、HDL 亚类、载脂蛋白 B 和餐后脂血症。西洛他唑可改善外周动脉疾病或 2 型糖尿病患者的致动脉粥样硬化血脂谱。需要进一步研究以确定西洛他唑治疗是否对高危患者的致动脉粥样硬化血脂异常产生临床相关影响。
